GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting
In Phase 3 trials so far, its delivered up to 28.7% body-weight loss at 68 weeks at the 12 mg dose in adults with obesity and knee osteoarthritis, alongside meaningful reductions in knee pain
"Obesity is a chronic disease and, just like any other chronic disease, it should be treated as such," a spokesperson for Novo Nordisk said
This central effect is a key reason why GLP-1 agonists are so effective for weight loss
In data presented at the conference, Roche reported that patients lost 22.7% of their bodyweight in a mid-stage trial of enicepatide, with a gastrointestinal side effect profile similar to existing GLP-1 drugs
A recent study found that GLP-1 drugs like Ozempic and Wegovy may improve breast cancer survival and recurrence in those with obesity and related health conditions